PT010

PT010

  • July 2018 •
  • 20 pages •
  • Report ID: 5780260 •
  • Format: PDF
Drug Overview
PT010 is a fixed triple-combination product consisting of a long-acting muscarinic antagonist (LAMA [glycopyrrolate]), a long-acting beta 2 agonist (LABA [formoterol]), and an inhaled corticosteroid (ICS [budesonide]). PT010 is in Phase III development for the treatment of moderate to very severe COPD, and in Phase II development for the treatment of moderate to severe persistent asthma.